Published: 20:13, November 20, 2026
HK joins global drug regulatory body, boosting medical innovation drive
By Yancy Fang in Hong Kong
This Sept 15, 2026 photo shows a view of Hong Kong Island. (ANDY CHONG/CHINA DAILY)

Hong Kong has formally joined the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) as a regulatory member, marking a milestone in the city's push to become an international health and medical innovation hub, the Health Bureau announced on Friday.

The ICH is an international body to harmonize global technical requirements for drug registration and to promulgate various guidelines on safety, efficacy and quality, which are recognized as the highest global standards for the protection of public health.

The accession, approved at the council's assembly meeting in the Czech Republic on Nov 17, makes Hong Kong — represented by the Pharmacy and Poisons Board of Hong Kong — the 20th regulatory member of the authoritative global platform for harmonizing drug regulation standards.

Other members include the National Medical Products Administration of China, as well as regulatory authorities from Europe, Switzerland, the United Kingdom, and the United States.

Expressing gratitude to the country for its continued support, Secretary for Health Lo Chung-mau said that the achievement demonstrates the unique advantages of the "one country, two systems" principle.

Lo said that Hong Kong fulfilled all requirements to attain full regulatory membership in just three years since becoming an ICH observer on Oct 31, 2023, significantly faster than the eight to 10 years initially estimated based on international experience.

ALSO READ: Health chief: HK making significant lifesaving progress against cancer

Looking ahead, Hong Kong will align its First Five-Year Plan (2026-2030) for Economic and Social Development with the National 15th Five-Year Plan to support clinical R&D in biomedicine and optimize evaluation mechanisms for innovative and urgently needed drugs, he added.

“The Hong Kong Special Administrative Region government will establish the Centre for Medical Products Regulation (CMPR) next month to build up capacity for independent drug evaluation and approval, and actively participate in international cooperation, with a view to developing Hong Kong into an international health and medical innovation hub and better integrating into and serving the overall national development,” Lo said.

READ MORE: HK launches online platform to resolve medical disputes

Ronald Lam, director of Health, described the accession as a key milestone for Hong Kong's regulatory reform, particularly for the upcoming CMPR.

Lam said that the center will assemble a professional team in accordance with ICH technical requirements, improve evaluation efficiency for innovative drugs, and deploy experts to help formulate and revise global regulatory guidelines.

“Hong Kong is now both an ICH regulatory member and a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). The CMPR will adopt a science-based approach and strive to become an internationally renowned regulatory authority,” he added.

On Jan 1, 2016, Hong Kong became a formal member of PIC/S, an international organization comprising pharmaceutical regulatory authorities from multiple countries and regions to harmonize Good Manufacturing Practice standards and quality systems among them.

 

Contact the writer at yancyfang@chinadailyhk.com